Visiongain Launches Report Examining the Potential in the $17bn Attention Deficit Hyperactivity Disorder Drugs Market

Attention Deficit Hyperactivity Disorder Drugs Market Forecast to 2029

Amphetamine, Methylphenidate Hydrochloride, Dexymethylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Clonidine, Stimulants, No-stimulants, Adults, Children, Retail Pharmacy, Hospital Pharmacy

News provided by

Visiongain

Nov 27, 2019, 05:00 ET

LONDON, Nov. 27, 2019 /PRNewswire/ -- The global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market is estimated to have reached $13.40bn in 2018 and is expected to grow at a CAGR of 4.43% in the first half of the forecast period. The stimulants submarket held 75% of the global Attention Deficit Hyperactivity Disorder (ADHD) Market in 2018.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 151-page report you will receive 124 charts– all unavailable elsewhere.

The 151-page Visiongain report provides clear detailed insight into the ADHD market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/attention-deficit-hyperactivity-disorder-drugs-market-forecast-to-2029/#download_sampe_div

Report Scope

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by leading drugs:
• Amphetamine
• Methylphenidate
• Lisdexamfetamine
• Dexmethylphenidate
• Atomoxetine
• Guanfacine
• Clonidine
• Other Drugs

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by drug type:
• Stimulants
• Non-stimulants

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by patient type:
• Adult
• Children

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 national market:
• The U.S.
• Germany
• France
• The U.K.
• Italy
• Spain
• China
• Japan
• India
• Brazil
• Russia

• This report discusses the selected leading companies:
• Eli Lilly
• Johnson and Johnson
• Lupin Limited
• Mallinckrodt & Co.
• Neos Therapeutics
• Pfizer Inc.
• Purdue Pharma L.P.
• Takeda Pharmaceuticals

• This report provides a SWOT Analysis and Porter's Five Forces Analysis of the Attention Deficit Hyperactivity Disorder Drugs market.

• Key questions answered by this report:
• How is the ADHD market evolving?
• What is driving and restraining the ADHD market?
• What are the market shares of each segment of the overall ADHD market in 2018?
• How will each ADHD submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each ADHD's submarket develop from 2018 to 2029?
• Which individual products will prevail and how will these shifts be responded to?
• What will be the main driver for the overall market from 2018 to 2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• Will leading national vaccine markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2029 and which geographical region will lead the market in 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2018 and 2029?

To request a report overview of this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/attention-deficit-hyperactivity-disorder-drugs-market-forecast-to-2029/

Did you know that we also offer a report add-on service? Email [email protected] to discuss any customized research needs you may have.

Companies covered in the report include:

Accerlant, Inc.
Actelion Pharmaceuticals Italia S.r.l.
Adlon Therapeutics L.P.
Alnara Pharmaceuticals, Inc
Apotex Inc
Aurobindo Pharma Limited
Cordis de Mexico, S.A. de C.V
DePuy International Limited
Dr. Reddy's
Elanco Australasia Pty. Ltd.
Elanco India Private Limited
Elanco Spain, S.L.
Eli Lilly
Glenmark Pharmaceuticals Limited
Greenfield Bioventur
Ikaria Australia Pty Ltd
Imbrium Therapeutics L.P.
Impax Laboratories
Janssen Pharmaceutical K.K.
Janssen-Cilag Pharma GmbH Austria
Johnson and Johnson
Lupin Pharmaceuticals
Mallinckrodt Canada ULC
Mallinckrodt International Holdings S.a r.l.
Mallinckrodt Pharmaceuticals
Mylan
Neos Therapeutics
Pfizer
Purdue Pharmaceuticals
Sandoz
Shingoi & CO. Ltd
Shire
Sun Pharma
Takeda Pharmaceuticals
Teva Pharmaceuticals USA Inc
TWi Pharmaceuticals